BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, Guimaraes A, Vangel MG, Mahmood U, Soricelli A. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer. 2015;112:1452-1460. [PMID: 25871331 DOI: 10.1038/bjc.2015.112] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 . MSK – Was können 18F-FDG-PET/MRT, MRT, CT und 'Szintigrafie bei der Detektion von Knochenmetastasen? Rofo 2022;194:823-4. [DOI: 10.1055/a-1754-6180] [Reference Citation Analysis]
2 Orcajo-Rincon J, Muñoz-Langa J, Sepúlveda-Sánchez JM, Fernández-Pérez GC, Martínez M, Noriega-Álvarez E, Sanz-Viedma S, Vilanova JC, Luna A. Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer. Clin Transl Oncol 2022;24:1290-310. [PMID: 35152355 DOI: 10.1007/s12094-022-02784-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bruckmann NM, Morawitz J, Fendler WP, Ruckhäberle E, Bittner A, Giesel FL, Herrmann K, Antoch G, Umutlu L, Kirchner J. A Role of PET/MR in Breast Cancer? Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fowler AM, Strigel RM. Clinical advances in PET–MRI for breast cancer. The Lancet Oncology 2022;23:e32-43. [DOI: 10.1016/s1470-2045(21)00577-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
5 Seifert R, Kersting D, Rischpler C, Opitz M, Kirchner J, Pabst KM, Mavroeidi IA, Laschinsky C, Grueneisen J, Schaarschmidt B, Catalano OA, Herrmann K, Umutlu L. Clinical Use of PET/MR in Oncology: An Update. Semin Nucl Med 2021:S0001-2998(21)00099-4. [PMID: 34980479 DOI: 10.1053/j.semnuclmed.2021.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bogdanovic B, Solari EL, Villagran Asiares A, McIntosh L, van Marwick S, Schachoff S, Nekolla SG. PET/MR Technology: Advancement and Challenges. Semin Nucl Med 2021:S0001-2998(21)00101-X. [PMID: 34969520 DOI: 10.1053/j.semnuclmed.2021.11.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Oprea-Lager DE, Cysouw MCF, Boellaard R, Deroose CM, de Geus-Oei LF, Lopci E, Bidaut L, Herrmann K, Fournier LS, Bäuerle T, deSouza NM, Lecouvet FE. Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Front Oncol 2021;11:772530. [PMID: 34869009 DOI: 10.3389/fonc.2021.772530] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Husseini JS, Balza R, Evangelista L, Cañamaque LG, Catalano OA. PET/MR for evaluation of musculoskeletal malignancies. Clin Transl Imaging. [DOI: 10.1007/s40336-021-00470-9] [Reference Citation Analysis]
9 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
10 Sertic M, Kilcoyne A, Catalano OA, Lee SI. Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT. Abdom Radiol (NY) 2021. [PMID: 34302185 DOI: 10.1007/s00261-021-03218-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Di Micco R, Santurro L, Gasparri ML, Zuber V, Cisternino G, Baleri S, Morgante M, Rotmensz N, Canevari C, Gallivanone F, Scifo P, Savi A, Magnani P, Neri I, Ferjani N, Venturini E, Losio C, Sassi I, Bianchini G, Panizza P, Gianolli L, Gentilini OD. PET/MRI for Staging the Axilla in Breast Cancer: Current Evidence and the Rationale for SNB vs. PET/MRI Trials. Cancers (Basel) 2021;13:3571. [PMID: 34298781 DOI: 10.3390/cancers13143571] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 de Mooij CM, Sunen I, Mitea C, Lalji UC, Vanwetswinkel S, Smidt ML, van Nijnatten TJA. Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients. Nucl Med Commun 2020;41:995-1004. [PMID: 32769814 DOI: 10.1097/MNM.0000000000001254] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Pirasteh A, Lovrec P, Pedrosa I. Imaging and its Impact on Defining the Oligometastatic State. Semin Radiat Oncol 2021;31:186-99. [PMID: 34090645 DOI: 10.1016/j.semradonc.2021.03.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C, Pugliese N, Rascato MG, Cappuccio I, Campagna G, Cerchione C, Vigliar E, Troncone G, Mascolo M, Franzese M, Castaldo R, Salvatore M, Pane F. PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. Ann Hematol 2021;100:1525-35. [PMID: 33909101 DOI: 10.1007/s00277-021-04537-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Husseini JS, Amorim BJ, Torrado-Carvajal A, Prabhu V, Groshar D, Umutlu L, Herrmann K, Cañamaque LG, Garzón JRG, Palmer WE, Heidari P, Shih TT, Sosna J, Matushita C, Cerci J, Queiroz M, Muglia VF, Nogueira-Barbosa MH, Borra RJH, Kwee TC, Glaudemans AWJM, Evangelista L, Salvatore M, Cuocolo A, Soricelli A, Herold C, Laghi A, Mayerhoefer M, Mahmood U, Catana C, Daldrup-Link HE, Rosen B, Catalano OA. An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. Eur J Nucl Med Mol Imaging 2021;48:1522-37. [PMID: 33619599 DOI: 10.1007/s00259-021-05198-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Furtado FS, Ferrone CR, Lee SI, Vangel M, Rosman DA, Weekes C, Qadan M, Fernandez-Del Castillo C, Ryan DP, Blaszkowsky LS, Hong TS, Clark JW, Striar R, Groshar D, Cañamaque LG, Umutlu L, Catalano OA. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol 2021;23:456-66. [PMID: 33415677 DOI: 10.1007/s11307-020-01569-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hancin EC, Borja AJ, Nikpanah M, Raynor WY, Haldar D, Werner TJ, Morris MA, Saboury B, Alavi A, Gholamrezanezhad A. PET/MR Imaging in Musculoskeletal Precision Imaging - Third wave after X-Ray and MR. PET Clinics 2020;15:521-34. [DOI: 10.1016/j.cpet.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ming Y, Wu N, Qian T, Li X, Wan DQ, Li C, Li Y, Wu Z, Wang X, Liu J, Wu N. Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer. Front Oncol 2020;10:1301. [PMID: 32903496 DOI: 10.3389/fonc.2020.01301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
19 Dodelzon K, McGinty G, Melsaether A. PET/MRI in breast cancer patients: Added value, barriers to implementation, and solutions. Clin Imaging 2020;68:24-8. [PMID: 32562923 DOI: 10.1016/j.clinimag.2020.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Pesapane F, Downey K, Rotili A, Cassano E, Koh DM. Imaging diagnosis of metastatic breast cancer. Insights Imaging 2020;11:79. [PMID: 32548731 DOI: 10.1186/s13244-020-00885-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
21 Zheng D, Liu Y, Liu J, Li K, Lin M, Schmidt H, Xu B, Tian J. Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to 18F-FDG PET/CT. Cancer Imaging 2020;20:39. [PMID: 32546207 DOI: 10.1186/s40644-020-00317-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Bruckmann NM, Sawicki LM, Kirchner J, Martin O, Umutlu L, Herrmann K, Fendler W, Bittner AK, Hoffmann O, Mohrmann S, Dietzel F, Ingenwerth M, Schaarschmidt BM, Li Y, Kowall B, Stang A, Antoch G, Buchbender C. Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients. Eur J Nucl Med Mol Imaging 2020;47:2816-25. [PMID: 32333068 DOI: 10.1007/s00259-020-04801-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
23 Thierfelder KM, Niendorf S, Gerhardt JS, Weber MD. [Bone tumors and metastases: tips for initial diagnosis and follow-up : Update 2019]. Radiologe 2020;60:169-78. [PMID: 31974747 DOI: 10.1007/s00117-019-00635-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Jokar N, Velez E, Shooli H, Dadgar H, Sadathosseini SA, Assadi M, Gholamrezanezhad A. Advanced modalities of molecular imaging in precision medicine for musculoskeletal malignancies. World J Nucl Med 2019;18:345-50. [PMID: 31933549 DOI: 10.4103/wjnm.WJNM_119_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ferrone C, Goyal L, Qadan M, Gervais D, Sahani DV, Zhu AX, Hong TS, Blaszkowsky LS, Tanabe KK, Vangel M, Amorim BJ, Wo JY, Mahmood U, Pandharipande PV, Catana C, Duenas VP, Collazo YQ, Canamaque LG, Domachevsky L, Bernstine HH, Groshar D, Shih TT, Li Y, Herrmann K, Umutlu L, Rosen BR, Catalano OA. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2020;47:1871-84. [PMID: 31705172 DOI: 10.1007/s00259-019-04558-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
26 Çelebi F. What is the Diagnostic Performance of 18F-FDG-PET/MRI in the Detection of Bone Metastasis in Patients with Breast Cancer? Eur J Breast Health 2019;15:213-6. [PMID: 31620678 DOI: 10.5152/ejbh.2019.4885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Schiano C, Franzese M, Pane K, Garbino N, Soricelli A, Salvatore M, de Nigris F, Napoli C. Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study. Cancers (Basel) 2019;11:E1444. [PMID: 31561604 DOI: 10.3390/cancers11101444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
28 Kogan F, Broski SM, Yoon D, Gold GE. Applications of PET-MRI in musculoskeletal disease. J Magn Reson Imaging 2018;48:27-47. [PMID: 29969193 DOI: 10.1002/jmri.26183] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
29 Helland F, Hallin Henriksen M, Gerke O, Vogsen M, Høilund-Carlsen PF, Hildebrandt MG. FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review. Diagnostics (Basel) 2019;9:E106. [PMID: 31461923 DOI: 10.3390/diagnostics9030106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
30 Hildebrandt MG, Lauridsen JF, Vogsen M, Holm J, Vilstrup MH, Braad PE, Gerke O, Thomassen M, Ewertz M, Høilund-Carlsen PF; Centre for Personalized Response Monitoring in Oncology (PREMIO). FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond. Cancers (Basel) 2019;11:E1190. [PMID: 31443324 DOI: 10.3390/cancers11081190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
31 Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D, Raderer M, Preusser M, Hochmair M, Kiesewetter B, Scheuba C, Ba-Ssalamah A, Karanikas G, Kesselbacher J, Prager G, Dieckmann K, Polterauer S, Weber M, Rausch I, Brauner B, Eidherr H, Wadsak W, Haug AR. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging 2020;47:51-60. [PMID: 31410538 DOI: 10.1007/s00259-019-04452-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
32 Ulaner GA. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? American Journal of Roentgenology 2019;213:254-65. [DOI: 10.2214/ajr.19.21177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
33 Morsing A, Hildebrandt MG, Vilstrup MH, Wallenius SE, Gerke O, Petersen H, Johansen A, Andersen TL, Høilund-carlsen PF. Hybrid PET/MRI in major cancers: a scoping review. Eur J Nucl Med Mol Imaging 2019;46:2138-51. [DOI: 10.1007/s00259-019-04402-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
34 Incoronato M, Grimaldi AM, Mirabelli P, Cavaliere C, Parente CA, Franzese M, Staibano S, Ilardi G, Russo D, Soricelli A, Catalano OA, Salvatore M. Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study. Cancers (Basel) 2019;11:E876. [PMID: 31234535 DOI: 10.3390/cancers11060876] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
35 Evangelista L, Cuppari L, Burei M, Zorz A, Caumo F. Head-to-head comparison between 18F-FDG PET/CT and PET/MRI in breast cancer. Clin Transl Imaging 2019;7:99-104. [DOI: 10.1007/s40336-019-00319-2] [Reference Citation Analysis]
36 Pujara AC, Kim E, Axelrod D, Melsaether AN. PET/MRI in Breast Cancer: PET/MRI in Breast Cancer. J Magn Reson Imaging 2019;49:328-42. [DOI: 10.1002/jmri.26298] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
37 Botsikas D, Bagetakos I, Picarra M, Da Cunha Afonso Barisits AC, Boudabbous S, Montet X, Lam GT, Mainta I, Kalovidouri A, Becker M. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer? Eur Radiol 2019;29:1787-98. [DOI: 10.1007/s00330-018-5720-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
38 Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer. PET Clinics 2018;13:355-61. [DOI: 10.1016/j.cpet.2018.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
39 Queiroz MA, Barbosa FG, Buchpiguel CA, Cerri GG. Positron emission tomography/magnetic resonance imaging (PET/MRI): An update and initial experience at HC-FMUSP. Rev Assoc Med Bras (1992) 2018;64:71-84. [PMID: 29561945 DOI: 10.1590/1806-9282.64.01.71] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Heller SL, Heacock L, Moy L. Developments in Breast Imaging: Update on New and Evolving MR Imaging and Molecular Imaging Techniques. Magn Reson Imaging Clin N Am 2018;26:247-58. [PMID: 29622129 DOI: 10.1016/j.mric.2017.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KS, Talenfeld AD, Nanus DM, Tagawa ST, Robinson BD, Rao RA, Pauli C, Bareja R, Beltran LS, Sigaras A, Eng KW, Elemento O, Sboner A, Rubin MA, Beltran H, Mosquera JM. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer 2018;124:1008-15. [PMID: 29266381 DOI: 10.1002/cncr.31173] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
42 Obara P, Loening A, Taviani V, Iagaru A, Hargreaves BA, Vasanawala S. Relative value of three whole-body MR approaches for PET-MR, including gadofosveset-enhanced MR, in comparison to PET-CT. Clin Imaging 2018;48:62-8. [PMID: 29031209 DOI: 10.1016/j.clinimag.2017.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Grueneisen J, Sawicki LM, Wetter A, Kirchner J, Kinner S, Aktas B, Forsting M, Ruhlmann V, Umutlu L. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients. European Journal of Radiology 2017;89:14-9. [DOI: 10.1016/j.ejrad.2016.12.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
44 Singnurkar A, Poon R, Metser U. Comparison of 18F-FDG-PET/CT and 18F-FDG-PET/MR imaging in oncology: a systematic review. Ann Nucl Med 2017;31:366-78. [PMID: 28353197 DOI: 10.1007/s12149-017-1164-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
45 Oehmigen M, Lindemann ME, Lanz T, Kinner S, Quick HH. Integrated PET/MR breast cancer imaging: Attenuation correction and implementation of a 16-channel RF coil. Med Phys 2016;43:4808. [PMID: 27487899 DOI: 10.1118/1.4959546] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
46 Melsaether A, Moy L. Breast PET/MR Imaging. Radiol Clin North Am 2017;55:579-89. [PMID: 28411681 DOI: 10.1016/j.rcl.2016.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
47 Kintzelé L, Weber M. Bildgebende Diagnostik bei Skelettmetastasen. Radiologe 2017;57:113-28. [DOI: 10.1007/s00117-016-0205-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Joo I, Lee JM, Lee DH, Lee ES, Paeng JC, Lee SJ, Jang J, Kim S, Ryu JK, Lee K. Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study. Radiology 2017;282:149-59. [DOI: 10.1148/radiol.2016152798] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
49 Zawlik I, Kaznowska E, Cebulski J, Kolodziej M, Depciuch J, Vongsvivut J, Cholewa M. FPA-FTIR Microspectroscopy for Monitoring Chemotherapy Efficacy in Triple-Negative Breast Cancer. Sci Rep 2016;6:37333. [PMID: 27857183 DOI: 10.1038/srep37333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
50 Riola-parada C, García-cañamaque L, Pérez-dueñas V, Garcerant-tafur M, Carreras-delgado J. Simultaneous PET/MRI vs. PET/CT in oncology. A systematic review. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2016;35:306-12. [DOI: 10.1016/j.remnie.2016.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, Garcerant-Tafur M, Carreras-Delgado JL. Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. Rev Esp Med Nucl Imagen Mol 2016;35:306-12. [PMID: 27424217 DOI: 10.1016/j.remn.2016.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
52 Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer. J Nucl Med 2016;57 Suppl 1:17S-26S. [PMID: 26834096 DOI: 10.2967/jnumed.115.157859] [Cited by in Crossref: 58] [Cited by in F6Publishing: 71] [Article Influence: 9.7] [Reference Citation Analysis]
53 Ho AM, Kalantari BN. PET/MRI: A New Frontier in Breast Cancer Imaging. Breast J 2016;22:261-3. [PMID: 27191359 DOI: 10.1111/tbj.12570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Kwon HW, Becker AK, Goo JM, Cheon GJ. FDG Whole-Body PET/MRI in Oncology: a Systematic Review. Nucl Med Mol Imaging 2017;51:22-31. [PMID: 28250855 DOI: 10.1007/s13139-016-0411-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
55 Melsaether AN, Raad RA, Pujara AC, Ponzo FD, Pysarenko KM, Jhaveri K, Babb JS, Sigmund EE, Kim SG, Moy LA. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer. Radiology 2016;281:193-202. [PMID: 27023002 DOI: 10.1148/radiol.2016151155] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 9.5] [Reference Citation Analysis]
56 Pugmire BS, Guimaraes AR, Lim R, Friedmann AM, Huang M, Ebb D, Weinstein H, Catalano OA, Mahmood U, Catana C, Gee MS. Simultaneous whole body 18F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with 18F-fluorodeoxyglucose positron emission tomography computed tomography. World J Radiol 2016; 8(3): 322-330 [PMID: 27028112 DOI: 10.4329/wjr.v8.i3.322] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mahajan A, Azad GK, Cook GJ. PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management. PET Clin. 2016;11:305-318. [PMID: 27321034 DOI: 10.1016/j.cpet.2016.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
58 Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, Antoch G, Kinner S. Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. European Journal of Radiology 2016;85:459-65. [DOI: 10.1016/j.ejrad.2015.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
59 Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med 2016;57:420-30. [PMID: 26742709 DOI: 10.2967/jnumed.115.158808] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 17.2] [Reference Citation Analysis]
60 Kuwert T, Ritt P. PET/MRI and PET/CT: is there room for both at the top of the food chain? Eur J Nucl Med Mol Imaging 2016;43:209-11. [DOI: 10.1007/s00259-015-3246-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]